How big is uniQure NV?

As of Jun 18, uniQure NV has a market capitalization of 809.73 million, with net sales of 20.21 million and a net profit of -217.58 million over the last four quarters. The balance sheet shows shareholder's funds of -6.75 million and total assets of 556.54 million.

As of Jun 18, uniQure NV has a market capitalization of 809.73 million, categorizing it as a Micro Cap company.<BR><BR>As of the latest four quarters, uniQure NV reported net sales of 20.21 million and a net profit of -217.58 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of -6.75 million and total assets of 556.54 million.

What does uniQure NV do?

uniQure NV is a Netherlands-based biotechnology company focused on developing gene therapies for genetic diseases, with recent net sales of $2 million and a net loss of $44 million. The company has a market cap of $809.73 million and does not currently pay dividends.

Overview:<BR>uniQure NV is a Netherlands-based company specializing in gene therapy within the Pharmaceuticals & Biotechnology industry, focusing on developing one-time administered treatments for genetic and other devastating diseases.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -44 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 809.73 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.76 <BR>Return on Equity: -666.88% <BR>Price to Book: 24.04<BR><BR>Contact Details:<BR>Address: Paasheuvelweg 25a, AMSTERDAM None: 1105 BP <BR>Tel: ['31 20 2406000', '1 339 9707536'] <BR>Fax: 31 20 2406020 <BR>Website: http://www.uniqure.com/

Who are in the management team of uniQure NV?

As of March 2022, the management team of uniQure NV includes CEO Matthew Kapusta, along with other executives and non-executive directors such as Philip Astley-Sparke (Chairman), Robert Gut, Leonard Post, Madhavan Balachandran, Jack Kaye, and David Meek.

As of March 2022, the management team of uniQure NV includes the following individuals:<BR><BR>- Mr. Philip Astley-Sparke: Independent Non-Executive Chairman of the Board<BR>- Mr. Matthew Kapusta: Chief Executive Officer, Chief Financial Officer, Executive Director<BR>- Dr. Robert Gut: Executive Director<BR>- Dr. Leonard Post: Director<BR>- Mr. Madhavan Balachandran: Non-Executive Independent Director<BR>- Mr. Jack Kaye: Non-Executive Independent Director<BR>- Mr. David Meek: Non-Executive Independent Director<BR><BR>In summary, the management team comprises a mix of executive and non-executive directors, with Mr. Matthew Kapusta serving in a dual role as CEO and CFO.

Should I buy, sell or hold uniQure NV?

Is uniQure NV overvalued or undervalued?

As of August 8, 2022, uniQure NV's valuation has shifted from fair to risky due to significant negative financial metrics, including a Price to Book Value of 28.07, an EV to EBITDA of -6.16, and a return on equity of -666.88%, making it appear overvalued despite a disappointing year-to-date stock performance of -16.53%.

As of 8 August 2022, the valuation grade for uniQure NV moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued given its significant negative financial metrics, including a Price to Book Value of 28.07 and an EV to EBITDA of -6.16. Additionally, its return on equity (ROE) stands at a staggering -666.88%, further highlighting its struggles.<BR><BR>In comparison to its peer, Precigen, Inc., which has a worse EV to EBITDA ratio of -13.1325, uniQure's valuation metrics still suggest it is not a favorable investment. The company's recent stock performance has been disappointing, with a year-to-date return of -16.53% compared to the S&P 500's positive return of 12.22%, reinforcing the notion that uniQure is currently overvalued.

Is uniQure NV technically bullish or bearish?

As of August 28, 2025, uniQure NV shows a bullish trend with positive MACD and OBV indicators, but mixed signals from RSI and Bollinger Bands suggest caution, especially given its underperformance against the S&P 500.

As of 28 August 2025, the technical trend for uniQure NV has changed from mildly bullish to bullish. The MACD is bullish on both the weekly and monthly time frames, indicating positive momentum. However, the RSI shows a bearish signal on the monthly, which suggests some caution. The Bollinger Bands are bearish weekly but mildly bullish monthly, indicating mixed signals. Moving averages are mildly bullish daily, while the KST is mildly bearish weekly but bullish monthly. Dow Theory supports a mildly bullish stance on both weekly and monthly charts, and OBV is bullish monthly, further supporting the positive outlook.<BR><BR>Despite the current bullish trend, the stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -16.53% compared to the S&P 500's 12.22%, and a 5-year return of -64.64% versus the S&P 500's 96.61%. Overall, the technical stance is bullish but with some mixed indicators suggesting caution.